With the new TheraKey, Berlin-Chemie takes the next step in digital therapy support

A tablet showing the new TheraKey website

Further development of the already strong information portal on the individual therapy support program.

The TheraKey portal provides patients, physicians and family members with scientifically sound information and accompanies patients in their therapy with helpful protocol functions, tools, quizzes and prescriptions.

The old TheraKey portal has already caused a sensation in the pharmaceutical world. With the new portal, BERLIN-CHEMIE and IBM iX have taken the next step in digital therapy support.

The new portal is friendlier, more structured and, above all, more personal. Users get the information relevant to them at the point where they need it. The improvement of the tools and quizzes used will increase user adherence and thus also make the doctor’s work easier. The TheraKey offers support for eight indications, including type 1 and type 2 diabetes as well as asthma and COPD (Chronic Obstructive Pulmonary Disease).

The technical basis is now ready for the future and has been implemented according to the current and high standards of data protection and security. The project was carried out in close cooperation with the Fraunhofer Institute for Digital Media Technology IDMT.

TheraKey as an extended arm of the physician

There are people who have to share their everyday life with an illness. For these people, TheraKey is the digital companion program that helps them live with their illness as well as possible, learn about therapy options, and read important information. Medical professionals use TheraKey as an extended arm for patients at home. In the old portal, all users saw the same content for each indication. This will now change, because every person is unique, has an individual clinical picture and needs a specific treatment along with a suitable program.

Patient with personality!

Our claim: This has to work better! Patients and their relatives should be able to access information that is only relevant to them more quickly. When logging in and entering the special code received from the responsible physician, users can now directly configure a personal profile and from now on will only be shown the personalized information relevant to his or her disease.

“Berlin-Chemie recognized early on the opportunities offered by digitalization. We don’t just want to manufacture medicines, but see our role as supporting people, identifying relevant issues and offering help – also and especially in dealing with digital offerings. With the TheraKey, we have done pioneering work in this regard and would like to continue to set new standards together with our agency partners such as IBM iX to enable greater adherence.”

Michael Bollessen

Product Group Manager for Diabetes Services Marketing, Berlin-Chemie AG